Literature DB >> 17531850

Multiple sclerosis in Isfahan, Iran.

Mohammad Saadatnia1, Masoud Etemadifar, Amir Hadi Maghzi.   

Abstract

BACKGROUND: This survey was planned to study the prevalence and incidence of multiple sclerosis (MS) in Isfahan, Iran and to describe the clinical features of MS in general and in specific subgroups of patients (early-onset, late-onset, familial, and conjugal cases) and to compare our results with other reports.
METHODS: A cross-sectional study was conducted from April 5, 2003 to July 31, 2006. All patients known to have definite MS according to McDonald's criteria, alive, resident within Isfahan (a large province of Iran) and members of Isfahan MS Society (IMSS) were included in the study. Demographic and case-related information were recorded. A total number of 1718 definite MS patients (388 men and 1330 women) were identified from IMSS database.
RESULTS: The overall period prevalence of MS was 43.8/100,000. Among men the prevalence was 19.2 (95% CI: 17.4-21.2)/100,000 and among women 69.6 (95% CI: 66-73.4)/100,000. A female preponderance of 3.4 existed among these patients. In the year 2005, 143 new cases were diagnosed, resulting in an incidence rate of 3.64/100,000. The mean age of onset was 25.36 +/- 8.6 years (range 5-63 year), and mean duration of disease was 7.1 (+/-5.2) years for men and 6.7 (+/-5) years for women. Sensory and visual disturbances were the most common initial presentations with a prevalence of 51.7% and 47.5%, respectively. Cases identified include: early-onset MS (less than 15 years old at onset) with 87 cases (5%), late-onset MS (over 50 years old at onset) with 20 cases (1.1%), familial MS with 209 cases (12.2%), and conjugal MS with 6 cases (0.5%).
CONCLUSION: Isfahan is a medium- to high-risk area for MS, with prevalence higher than what has previously been reported, possibly because of an increase in the incidence rate. Clinical and demographic characteristics were similar to other reports; however, some differences existed.

Entities:  

Mesh:

Year:  2007        PMID: 17531850     DOI: 10.1016/S0074-7742(07)79016-5

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  33 in total

Review 1.  Cognitive Assessment of Individuals with Multiple Sclerosis in the Arab World: a Systematic Review.

Authors:  Samira Paul; Aeysha Brown; Abbey J Hughes
Journal:  Neuropsychol Rev       Date:  2019-05-17       Impact factor: 7.444

2.  Prevalence of MS in Iranian immigrants to British Columbia, Canada.

Authors:  Colleen Guimond; David A Dyment; Sreeram V Ramagopalan; Gavin Giovannoni; Maria Criscuoli; Irene M Yee; George C Ebers; A Dessa Sadovnick
Journal:  J Neurol       Date:  2009-12-10       Impact factor: 4.849

3.  Co-occurrence of multiple sclerosis and Thomsen's myotonia: a report of two cases.

Authors:  Fereshteh Ashtari; Seyed Amir Bahreini; Hamid Zahednasab
Journal:  Funct Neurol       Date:  2014 Oct-Dec

Review 4.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

5.  Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.

Authors:  Masoud Etemadifar; Amir Hossein Sarrami
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

6.  Multiple sclerosis in Isfahan, Iran: Past, Present and Future.

Authors:  Masoud Etemadifar; Seyed-Hossein Abtahi
Journal:  Int J Prev Med       Date:  2012-05

7.  Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.

Authors:  Shekoufeh Nikfar; Abbas Kebriaeezadeh; Rassoul Dinarvand; Mohammad Abdollahi; Mohammad-Ali Sahraian; David Henry; Ali Akbari Sari
Journal:  Daru       Date:  2013-06-22       Impact factor: 3.117

8.  The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis.

Authors:  Naeim Ehtesham; Maryam Zare Rafie; Meysam Mosallaei
Journal:  BMC Neurol       Date:  2021-06-28       Impact factor: 2.474

9.  Can vitamin d suppress endothelial cells apoptosis in multiple sclerosis patients?

Authors:  Leila Dehghani; Rokhsareh Meamar; Masoud Etemadifar; Zahra Dehghani Sheshde; Vahid Shaygannejad; Mostafa Sharifkhah; Soheil Tahani
Journal:  Int J Prev Med       Date:  2013-05

10.  Vitamin d3 concentration correlates with the severity of multiple sclerosis.

Authors:  Saeed Shahbeigi; Hossein Pakdaman; Seyed-Mohammad Fereshtehnejad; Elham Nikravesh; Nazanin Mirabi; Ghazal Jalilzadeh
Journal:  Int J Prev Med       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.